Compare AbbVie Inc (ABBV) vs GXO Logistics Inc (GXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs GXO Logistics Inc — how do they compare? AbbVie Inc trades at $248.3 (market cap $441.94B), while GXO Logistics Inc trades at $47.99 (market cap $5.37B). The key difference: AbbVie Inc is far larger — about 82.3× GXO Logistics Inc's market cap, and AbbVie Inc pays a 2.77% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| ABBV | GXO | |
|---|---|---|
Market Cap | $441.94B | $5.37B |
Sector | Health | Industrials |
52-Week High | $263.58 | $65.59 |
52-Week Low | $197.38 | $45.52 |
Enterprise Value | $506.19B | $10.72B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
GXO Logistics trades at $47.85, up 1.9% in the last session, with a bearish technical signal but strong analyst backing. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.59 exceeding expectations, and revenue growth to $13.6 billion in 2026. However, margins remain tight, with a net income margin of 0.96%, and the P/E ratio of 41.3 suggests high valuation relative to earnings.
The outlook is mixed: bullish analyst consensus, with 88.9% buy ratings and a $65.67 price target, indicates potential upside, but stagnant margins and bearish technicals pose risks. Investors should weigh strong business wins against cost absorption challenges highlighted in recent earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
